In the early phase I clinical trials, GR-MD-02, a Gal-3 inhibitor, was well tolerated in patients with fatty liver disease/non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis [91]. This evidence concerns the gene LGALS3 and metabolic dysfunction-associated steatohepatitis.